The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...

Labeling would drop the limitation of use for age-related hypogonadism, reflecting an evidence reassessment that no longer supports language implying unestablished safety and effectiveness in this ...

FDA cleared Titan Prime, a next-generation IPP, emphasizing improved flaccid flexibility intended to enhance comfort and concealability for erectile dysfunction patients. Approval of generic Ga-68 ...

The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin. This decision marks the first approval of an oral carbapenem ...

RELIEF uses a prospective, single-arm design to generate initial safety and preliminary efficacy signals for transperineal transition-zone IRE as a non-resecting BPH/LUTS intervention. Eligibility ...

Live Events | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.